Heptares and ICL sign gastrointestinal R&D pact
Heptares Therapeutics, the UK-headquartered wholly-owned subsidiary of Japan’s Sosei Group, has formed a new drug research and development pact with…
RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease
RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal…